The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009
"The Rapid-Fire Innovation Session at LabAutomation2009 provides an opportunity for scientists and engineers to learn about innovative technologies that can enhance and improve the capabilities and productivity of R&D labs," says Dr. Karen Donato, Vice President of Sales and Marketing, who will be presenting the MaxCyte STX technology in the session. "The selection of the MaxCyte STX for this session attests to the uniqueness of MaxCyte's large scale transfection technology. Using the MaxCyte STX, more than ten billion cells can be transfected in less than 30 minutes with one or more loading agents at efficiencies and cell viabilities often exceeding 90%. The speed, scale, and flexibility of our technology allow the development of an expanded range of relevant cell-based assays for drug discovery. We are pleased to have the opportunity to present and demonstrate the MaxCyte STX technology at LabAutomation2009."
"The MaxCyte STX is being viewed by the pharmaceutical industry as an innovative and enabling technology for cell modification for both research and large scale cell-based applications in drug discovery," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce billions of high quality transfected cells in minutes compared to time consuming and inconsistent alternative methods. With the infinite number of combinations of cell types and loading agents that can be processed reproducibly with the MaxCyte STX, drug discovery scientists now have a powerful tool for modifying cells in ways that will improve the design, development, and conduct of screening assays, increasing the likelihood of finding successful drug candidates."
MaxCyte will also be participating in LabAutomation2009 as an exhibitor and offering demonstrations of the MaxCyte STX during the conference.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte(R) STX(TM) Scalable Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cellbased applications.
For more information, http://www.maxcyte.com/cell-based-screening.shtml.
SOURCE MaxCyte, Inc.
You May Also Like